ArticleFrontiers in oncology2025

Pembrolizumab for treatment-related neuroendocrine prostate carcinoma with a high tumor mutational burden: a case report.

Keiji Shiba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.